Indications:

• Advanced prostate cancer
• Endometriosis
• Central precocious puberty
• Uterine fibroids
• Some cases of infertility

Mechanism of Action: Leuprorelin acts as an agonist at pituitary GnRH receptors. With continuous administration, it initially stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). However, with chronic use, it suppresses these hormones, leading to decreased testosterone in males and decreased estrogen in females.

Pharmacokinetics:

• Absorption: Depends on the formulation. Long-acting forms are developed to slowly release the drug.
• Distribution: Distributed widely in the body.
• Metabolism: Minimal metabolism, with the majority of the drug remaining intact.
• Excretion: Excreted primarily through the kidneys.

Form: Leuprorelin API is usually available as a white to off-white powder.